Relacorilant plus nab-paclitaxel demonstrated improved PFS and OS in platinum-resistant ovarian cancer.

Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant cases A drug originally used to treat a rare disease could extend the lives of patients with an aggressive form of ovarian cancer, according to a clinical trial. Platinum-resistant ovarian cancer occurs when the disease progresses within six months of starting platinum-based chemotherapy. This form of chemotherapy is different from other types because it uses compounds that contain platinum to destroy cancer cells by preventing them from dividing. Continue reading...

Relacorilant, a first-in-class selective glucocorticoid receptor antagonist, increases a tumour's sensitivity to chemotherapy by reducing cortisol sig…

Glucocorticoid receptor antagonist relacorilant is approved in combination with nab-paclitaxel

FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Patients treated with relacorilant were more likely to maintain hypertension control compared with patients treated with placebo. The findings support consideration of relacorilant as a therapeutic op...

Relacorilant is currently under review by the FDA for approval

Corcept will resubmit its NDA for relacorilant to treat Cushing’s syndrome after positive FDA feedback.

The approval of relacorilant for use in patients with platinum-resistant ovarian cancer is sought from the European Medicines Agency.

Lucy Gilbert, MD, MSc, FRCOG, discusses data from the ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

CHMP has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer.

Relacorilant plus nab-paclitaxel cuts death risk by 35% and extends survival to 16 months in platinum-resistant ovarian cancer, per final ROSELLA trial data.

Relacorilant plus nab-paclitaxel cuts death risk by 35% and extends survival to 16 months in platinum-resistant ovarian cancer, per final ROSELLA trial data.

Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant cases

Preliminary results found that combining relacorilant with nab-paclitaxel improved outcomes for women with advanced ovarian cancer.

Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant cases

Corcept Therapeutics’ relacorilant has